Clinical trial
Pulmonart: Docetaxel - Non-Small Cell Lung Cancer (NSCLC)
NCT00174772 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00174772 |
|---|---|
| Title | Pulmonart: Docetaxel - Non-Small Cell Lung Cancer (NSCLC) |
| Official title | A Two Arm Phase II Study Comparing Docetaxel/Cisplatin Induction Therapy Followed By Concurrent Chemoradiotherapy Versus Concurrent Chemoradiotherapy Followed By Consolidation Docetaxel/Cisplatin in Patients With Locally Advanced Unresectable NSCLC (Stage IIIA-Multiple cN2 or IIIB) |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Neoplasms |
| Intervention type | Drug |
| Interventions | docetaxel and cisplatin followed by concurrent chemoradiotherapy with docetaxel and cisplatin + radiotherapy, docetaxel and cisplatin + radiotherapy followed by docetaxel and cisplatin |
| Enrollment | 72 |
| Start date | Mar 1, 2004 |
| Primary completion | Feb 1, 2009 |
| Completion | Feb 1, 2009 |
| First posted | Sep 15, 2005 |
| Last update posted | Feb 17, 2010 |
| Countries | Belgium, Finland, France, Italy, Netherlands, Spain, Turkey (Türkiye), United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: